IND/GLY/MF a.m. | IND/GLY/MF p.m. | Placebo | Total | |
Patients | 35 | 35 | 36 | 37 |
Number of patients with ≥1 adverse event | 18 (51.4) | 23 (65.7) | 18 (50.0) | 32 (86.5) |
Headache | 5 (14.3) | 3 (8.6) | 7 (19.4) | 10 (27.0) |
Nasopharyngitis | 2 (5.7) | 2 (5.7) | 5 (13.9) | 8 (21.6) |
Oropharyngeal pain | 3 (8.6) | 4 (11.4) | 2 (5.6) | 7 (18.9) |
Cough | 1 (2.9) | 2 (5.7) | 1 (2.8) | 4 (10.8) |
Dysphonia | 2 (5.7) | 3 (8.6) | 1 (2.8) | 4 (10.8) |
Asthma | 1 (2.9) | 1 (2.9) | 1 (2.8) | 3 (8.1) |
Throat clearing | 1 (2.9) | 1 (2.9) | 0 (0.0) | 2 (5.4) |
Data are presented as n or n (%). MedDRA: Medical Dictionary for Regulatory Activities; IND: indacaterol acetate; GLY: glycopyrronium bromide; MF: mometasone furoate.